New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
07:06 EDTATRSAntares Pharma announces positive results from MTX Medi-Jey study
Antares Pharma announced positive results from an open-label, randomized, crossover study comparing the systemic availability of MTX Medi-Jet to oral methotrexate in adult patients with rheumatoid arthritis. This study was designed to compare the relative systemic availability of MTX following oral administration to subcutaneous (SC) self-administered MTX using the Medi-Jet device. Patients were assigned to one of four dose levels of MTX, 10 mg, 15 mg, 20 mg, and 25 mg. Results showed that the systemic availability of methotrexate following oral dosing plateaus above 15 mg. Following administration of MTX with Medi-Jet, the systemic availability increased proportionally at every dose, which will extend the range of exposure compared to patients receiving oral therapy.
News For ATRS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
09:07 EDTATRSFDA making testosterone product makers change labeling
Subscribe for More Information
February 25, 2015
07:12 EDTATRSAntares Pharma announces QuickShot testosterone study met primary endpoint
Antares Pharma announced positive top-line pharmacokinetic results that showed that the primary endpoint was achieved in the company’s ongoing, multi-center, phase 3 clinical study evaluating the efficacy and safety of testosterone enanthate administered once-weekly by subcutaneous injection using the QuickShot auto injector in testosterone deficient adult males. In the study, 150 adult males with hypogonadism low testosterone and testosterone blood levels less than 300 ng/dL received a starting dose of 75 mg of subcutaneously administered testosterone enanthate once weekly for six weeks. Blinded adjustments to dose were made when necessary at week seven based upon the week six pre-dose blood level, and full pharmacokinetic profiles were obtained during the 12th week of treatment. One hundred fifty patients have received at least one dose of study drug and to date, there have been no reported deaths and one serious adverse event of hospitalization for worsening depression. This patient received a single dose of QS T, and the SAE was not considered to be related to study drug. Thus far, there have been no reported adverse events consistent with urticaria. The FDA has recommended that the company create a larger safety database, including approximately 350 subjects exposed to QS T with 200 subjects exposed for six months and 100 subjects exposed for a year. Based on the number of subjects in previous studies and in the current phase 3 study, the company anticipates that it may need approximately 70 additional subjects exposed to QS T for six months.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use